Hormone replacement therapy (HRT) and endometrial morphology under consideration of the different molecular pathways in endometrial carcinogenesis

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 122, Issue 1, 2005, Pages 4-12

  Horn, Lars Christian ^a   Dietel, Manfred ^b   Einenkel, Jens ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Endometrial and cancer; Endometrial hyperplasia; Endometrium; Estrogen; Hormone replacement therapy; Hormones

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GESTAGEN; MEDROXYPROGESTERONE ACETATE; TAMOXIFEN; TIBOLONE;

BREAST CARCINOMA; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; ECHOGRAPHY; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; GENE MUTATION; GENETIC POLYMORPHISM; GERMANY; HORMONE SUBSTITUTION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; UNITED STATES;

EID: 24644442310     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2005.02.018     Document Type: Review

References (59)

1. C. Wilken-Jensen, and B. Ottesen The aging woman: The role of medical therapy Int J Gynecol Obstet 82 2003 381 391
2. World Population Aging 1950-2050 2002 Population Division, DESA Geneva, United Nations p. 29-32
3. Writing Group for the Women's Health Initiative Investigators Risks and benefits from estrogen plus progestin in healthy postmenopausal women JAMA 288 2002 321 333
4. R.T. Chlebowski, S.L. Hendrix, and R.D. Langer WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative randomised controlled trial JAMA 289 2003 3243 3253
5. Million Women Study Collaborators Breast cancer and hormone replacement therapy in the Million Women Study Lancet 362 2003 419 427
6. S. Hulley, D. Grady, and T. Bush Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausel women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group JAMA 380 1998 605 613
7. N.L. Keatin, P.D. Claery, A.S. Rossi, A.M. Zaslavsky, and J.Z. Ayanian Use of hormone replacement therapy by postemenopausal women in the United States Ann Intern Med 130 1999 545 553
8. C. Thiel, L.A.J. Heinemann, and A. Assmann Reasons for the changing use of HRT from the perspective of woman. Results of the German cohort study on women's health Zentralbl Gynakol 123 2001 390 398
9. H. Löwel, M. Heier, A. Schneider, U. Gösele, and C. Meisinger Hormontherapie - Ergebnisse aus dem KORA-Survey Dtsch Ärztebl 100 2003 2133 2134
10. B. Lawton, S. Rose, D. McLeod, and A. Dowell Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: Cross sectional survey of users BMJ 327 2003 845 846
11. H.J. Ahrendt, C. Brucker, and G. Göretzlehner HRT und Brustkrebs Frauenarzt 44 2003 1048 1051
12. Brucker C, Ahrendt HJ, Göretzlehner G, et al. Stellungnahme zur Frage, "Hormonersatztherapie und Brustkrebs" unter kritischer Würdigung neuer Studienergebnisse. Forum DKG 5/2003; p. 9-11
13. C. Keck, and C. Tempfer Hormone replacement therapy and breast cancer screening Geburtsh Frauenheilk 63 2003 999 1003
14. H.L. Olsson, C. Ingvar, and A. Bladstrom Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden Cancer 97 2003 1387 1392
15. D.W. Sturdee, and A.H. MacLennan Is combined estrogen/progestogen hormone therapy worth the risk? Climacteric 6 2003 177 179
16. J.P.A. Baak, E.C.M. Wisse-Brekelmans, J.C. Fleege, H.W.H.M. van der Putten, and P.D. Bezemer Assessment of the risk of endometrial cancer in hyperplasia by means of morphological and morphometrical features Pathol Res Pract 188 1992 856 859
17. L.C. Horn, U. Schurrbusch, K. Bilek, B. Hentschel, and J. Einenkel Risk of progression in complex and atypical endometrial hyperplasia: Clinicopathologic analysis in cases with and without progestogen treatment Int J Gynecol Cancer 14 2004 348 353
18. K.M. Feeley, and M. Wells Hormone replacement therapy and the endometrium J Clin Pathol 54 2001 435 440
19. L.C. Horn, S.F. Lax, M. Höckel, U. Fischer, and D. Schmidt Precancerous lesions of the endometrium: A review of the molecular pathogenesis and problems in terminology Geburtsh Frauenheilk 61 2001 8 14
20. S.L. Nand, M.A. Webster, R. Baber The Oestrogen/Provera Study Group Bleeding pattern and the endometrial changes during continuous combined hormone replacement therapy Obstet Gynecol 91 1998 678 684
21. R. Sitruk-Warre Progestogens in hormonal replacement therapy: New molecules, risks and benefits Menopause 9 2002 6 15
22. V. Beral, E. Banks, and G. Reeves Evidence from randomised trials on the long-term effects of hormone replacement therapy Lancet 360 2002 942 944
23. M.C. Pike, R.K. Peters, and W. Cozen Estrogen-progestin replacement therapy and endometrial cancer J Natl Cancer Inst 89 1997 1110 1116
24. E. Weiderpass, H.O. Adami, and J.A. Baron Risk of endometrial cancer following estrogen replacement with and without progestagens J Natl Cancer Inst 91 1999 1131 1137
25. G.L. Anderos, H.L. Judd, and A.M. Kaunitz Women's Health Initiative Investigator Effects of estrogen plus progestin on gynaecologic cancers and associated diagnostic procedures: The Women's Health Initative randomised trial JAMA 290 2003 1739 1748
26. B. Hanstein, T. Flötotto, D. Luke, D. Niederacher, M.W. Beckmann, and H.G. Bender Expression of the estrogenreceptor-β-splice-variant ER-β2 in gynecologic neoplasms Geburtsh Frauenheilk 60 Suppl. 1 2000 S37
27. M. Dowsett, and A. Ashworth New biology of the oestrogen receptor Lancet 362 2003 260 262
28. I. Iwamoto, T. Fujino, T. Douchi, and Y. Nagata Association of estrogen receptor alpha and beta3-adrenergic receptor polymorphisms with endometrial cancer Obstet Gynecol 102 2003 506 511
29. Brinton LA, Hoover RN, the Endometrial Cancer Collaborative Group. Estrogen replacement therapy and endometrial cancer risk: Unresolved issues. Obstet Gynecol 1993;81:265-71.
30. V. Beral The Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 364 2003 419 427
31. J.L. Burton, and M. Wells Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium Histopathology 33 1998 297 303
32. Y. Ichikawa, H. Tsunoda, K. Takano, A. Oki, and H. Yoshikawa Microsatellite instability and immunohistochemical analysis of MLH1 and MSH2 in normal endometrium, endometrial hyperplasia and endometrial cancer from hereditary nonpolyposis colorectal cancer patients Jpn J Clin Oncol 32 2002 110 112
33. R.Y. Yantiss, P.B. Clement, and Young RH Neoplastic and pre-neoplastic changes in gastrointestinal endometriosis Am J Surg Pathol 24 2000 513 524
34. G.M. Zanetta, M.J. Webb, H. Li, and G.L. Keeney Hyperestrogenism: A relevant risk factor for the development of cancer from endometriosis Gynecol Oncol 79 2000 18 22
35. D.M. Purdie, C.J. Bain, and V. Siskind Hormone replacement therapy and risk of epithelial ovarian cancer Br J Cancer 81 1999 559 563
36. A. Jemal, T. Murray, A. Samuels, A. Ghafoor, E. Ward, and M.J. Thun Cancer statistics CA Cancer J Clin 53 2003 5 26
37. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland. Eigenverlag, Saarbrücken 2002, p. 56-9. www.rki.de/KREBS.
38. S.F. Lax, B. Kendall, H. Tashiro, Slebos RJC, and L. Hedrick Analysis of p53 and K-ras mutations and microsatellite instability suggests distinct molecular genetic pathways in the pathogenesis of uterine endometrioid and serous carcinoma Cancer 88 2000 814 824
39. S.F. Lax, E.S. Pizer, B.M. Ronnett, and R.J. Kurman Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression Hum Pathol 29 1998 551 558
40. M.E. Sherman, and R.J. Kurman Evolving concepts in endometrial carcinogenesis: Importance of DNA repair and deregulated growth Hum Pathol 29 1998 1035 1038
41. D.E. Marsden, and N.F. Hacker The classification, diagnosis and management of endometrial hyperplasia Rev Gynaecol Pract 3 2003 89 97
42. T. Pérez-Medina, G. Folgueira, J. Haya, and P. Ortega Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: Long-term follow up Gynecol Oncol 73 1999 299 304
43. T.C. Randall, and R.J. Kurman Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40 Obstet Gynecol 90 1997 434 440
44. J. Visser de, A. Coert, H. Feenstra, and J. Vies van der Endocrinological studies with (7α 17α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20- yn-3-one (Org OD 14) Arzneimittelforschung 34 1984 1010 1017
45. L.A. Ross, and E.M. Adler Tibolone and climacteric symptoms Maturitas 21 1995 127 136
46. W. Hänggi, N. Bersinger, H.J. Altermatt, and M.H. Birhäuser Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users Maturitas 27 1997 133 143
47. W. Volker, H.J. Coelingh-Bennik, and F.A. Helmond Effects of tibolone on the endometrium Climacteric 4 2001 203 208
48. M. Varras, D. Polyzos, and C. Akrivis Effects of tamoxifen on the human female genital tract: Review of the literature Eur J Gynaecol Oncol 24 2003 258 268
49. J.L. Wilder, S. Shajahan, and N.H. Khattar Tamoxifen-associated malignant endometrial tumors: Pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study Gynecol Oncol 92 2004 553 558
50. E. Petru, S. Kurschel, and K. Walsberger Screening asmyptomatischer Frauen auf Endometriumkarzinom mit besonderer Berücksichtigung des Screenings unter Tamoxifen-Behandlung Geburtsh Frauenheilk 60 2000 297 301
51. P. Watson, and H.T. Lynch Cancer risk in mismatch repair gene mutation carriers Fam Cancer 1 2001 57 60
52. D.E. Boks, A.P. Trujillo, A.C. Voogd, H. Morreau, G.G. Kenter, and H.F. Vasen Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer Int J Cancer 10 2002 198 200
53. J.C. Huber, C. Schneeberger, and C.B. Tempfer Genetic modelling of the estrogen metabolism as a risk factor of hormone dependent disorders Maturitas 20 2002 1 12
54. Y. Tsuchiya, M. Nakajima, S. Kyo, T. Kanaya, M. Inoue, and T. Yokoi Human CYP1B1 is regulated by estradiol via estrogen receptor Cancer Res 64 2004 3119 3125
55. D. Dai, E.S. Litman, E. Schonteich, and K.K. Leslie Progesterone regulation of activating protein-1 transcriptional activity: A possible mechanism of progesterone inhibition of endometrial cancer cell growth J Steroid Biochem Mol Biol 87 2003 123 131
56. G. Emons, A. Huschmand-Nia, T. Krauss, and B. Hinney Hormone replacement therapy and endometrial cancer Onkologie 27 2004 207 210
57. L. Holmberg, and H. Anderson HABITS steering and data monitoring committee HABITS (hormonal replacement therapy after breast cancer - is it safe?); a randomised comparison: trial stopped Lancet 363 2004 453 455
58. A. Benshushan, O. Platiel, N. Rojansky, A. Brzezinski, and N. Laufer IUD use and the risk of endometrial cancer Eur J Obstet Gynecol Reprod Biol 105 2002 166 169
59. L.O. Wollter-Svensson, E. Stadberg, K. Andersson, L.A. Mattsson, V. Odlind, and I. Persson Intrauterine administration of levonorgestrel 5 and 10 μg/24 h in perimoneopausal hormone replacement therapy. A randomised clinical study during one year Acta Obstet Gynecol Scand 76 1997 449 454